Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~General Inclusion Criteria (All Participants):~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Life expectancy of \>/= 12 weeks~Inclusion Criteria Specific to Arms A, C and E (R/R MM):~* Arm A only: Must have R/R MM for which no established therapy for MM is appropriate and available or be intolerant to those established therapies~* Arms C and E only: Participants with R/R MM who have received at least 3 prior lines of therapy.~* Measurable disease defined by laboratory test results.~Inclusion Criteria Specific to Arms B and D (R/R NHL):~* Participants with histologically confirmed B-cell NHL who have relapsed or failed to respond to at least two prior systemic treatment regimens and for which no suitable therapy of curative intent or higher priority exists.~* Must have at least one bi-dimensionally measurable lesion.~Exclusion Criteria:~General Exclusion Criteria (All Participants):~* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, hormonal therapy, and/or radiotherapy, within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to initiation of study treatment~* Prior treatment with any anti-TIGIT agent~* Prior treatment with chimeric antigen receptor-T (CAR-T) therapy within 12 weeks before first study drug administration~* Autologous Stem-Cell Transplantation (ASCT) within 100 days prior to first study drug administration~* Active or history of autoimmune disease or immune deficiency~* Known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection at study enrollment, or any major episode of infection within 4 weeks prior to first study drug administration~Exclusion Criteria Specific to Arms A, C and E (R/R MM):~* Primary or secondary plasma cell leukemia~* Current or history of CNS involvement by MM~Exclusion Criteria Specific to Arms B and D (R/R NHL):~* Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab~* Current or history of CNS lymphoma~* Current eligibility for ASCT~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Tiragolumab R/R MM (Type: EXPERIMENTAL): Participants with relapsed or refractory (R/R) Multiple Myeloma (MM) will receive a single dose of 600 mg tiragolumab by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W).
- Arm B: Tiragolumab R/R NHL (Type: EXPERIMENTAL): Participants with relapsed or refractory (R/R) non-Hodgkin Lymphoma (NHL) will receive a single dose of 600 mg tiragolumab by IV infusion Q3W.
- Arm C: Tiragolumab + Daratumumab R/R MM (Type: EXPERIMENTAL): Participants with R/R MM will receive 600 mg tiragolumab Q3W + daratumumab by subcutaneous (SC) injection.
- Arm D: Tiragolumab + Rituximab R/R NHL (Type: EXPERIMENTAL): Participants with R/R NHL will receive 600 mg tiragolumab Q3W + rituximab by IV infusion and SC injection (optional).
- Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MM (Type: EXPERIMENTAL): Participants with R/R MM will receive 600 mg tiragolumab Q3W + atezolizumab by IV infusion Q3W + daratumumab by SC injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues